Back to top

Image: Bigstock

Trump Applauds SoftBank Investment, Targets High Drug Prices

Read MoreHide Full Article

On today’s episode of the Zacks Friday Finish Line podcast, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week’s biggest story: Donald Trump’s latest round of deals and promises.

The hosts kicked the show off with a look at Starbuck (SBUX - Free Report) . The company appears to be doubling down on its premium offerings and has pledged a significant expansion of its “Roastery” and “Reserve” concepts. Co-founder Howard Schultz will be stepping down from his role as his CEO to focus on promoting the new brands.

Find out more here: Starbucks News: $10 Coffee, Its Next Five Years, Princi is a Go

Next up was the news that Apple’s (AAPL - Free Report) Apple Music streaming service has hit 20 million paying subscribers. In just a year and a half, Apple has accumulated nearly half the number of subscribers that Spotify has in about eight years. We’ve truly reached a key moment for the music streaming industry.

More details here: Apple Music Achieves 20 Million Paying Subscribers

Maddy and Ryan also touched on a few earnings reports from this week, including Lululemon (LULU - Free Report) , Costco (COST - Free Report) , and Dave and Buster’s (PLAY - Free Report) , which sparked a discussion on why the arcade-restaurant concept has performed so well this year.

More on Dave and Buster’s: Dave & Buster's Just Hit a New 52-Week High

Finally, this week’s top story was more news from President-elect Donald Trump. The perpetual deal maker was at it again this week, this time teaming up with SoftBank (SFTBY - Free Report) to announce a $50 billion investment in the United States that will potentially create 50,000 new jobs. The announcement sent SoftBank and Sprint (S - Free Report) , which is 82%-owned by SoftBank, soaring this week.

Trump also sent biotech investors into a selling frenzy on Wednesday when he told Time, which just declared him “Person of the Year,” that he would target high drug price hikes.

Find out more on both stories here: SoftBank and Sprint Soaring on Trump-backed Investment Plan & Trump Vows to Slash Drug Prices, Sends Biotech Stocks Lower

As always, thanks for checking out this week’s episode of the Zacks Friday Finish Line, and make sure to check back next week for even more news from the investment and financial world!

Stocks that Aren't in the News. Yet.

You are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street. They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015 with a stellar average gain of +26% per year. See these high-potential stocks free >>